CN1976951B - 抗EpCAM免疫球蛋白 - Google Patents

抗EpCAM免疫球蛋白 Download PDF

Info

Publication number
CN1976951B
CN1976951B CN2005800099764A CN200580009976A CN1976951B CN 1976951 B CN1976951 B CN 1976951B CN 2005800099764 A CN2005800099764 A CN 2005800099764A CN 200580009976 A CN200580009976 A CN 200580009976A CN 1976951 B CN1976951 B CN 1976951B
Authority
CN
China
Prior art keywords
epcam
immunoglobulin
cancer
serum
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800099764A
Other languages
English (en)
Chinese (zh)
Other versions
CN1976951A (zh
Inventor
马尔特·彼得斯
马赛厄斯·洛彻
纳德贾·普朗
科尼利亚·奎特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Micromet GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet GmbH filed Critical Micromet GmbH
Publication of CN1976951A publication Critical patent/CN1976951A/zh
Application granted granted Critical
Publication of CN1976951B publication Critical patent/CN1976951B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN2005800099764A 2004-02-13 2005-02-09 抗EpCAM免疫球蛋白 Expired - Fee Related CN1976951B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/778,915 2004-02-13
US10/778,915 US20050180979A1 (en) 2004-02-13 2004-02-13 Anti-EpCAM immunoglobulins
PCT/EP2005/001307 WO2005080428A2 (en) 2004-02-13 2005-02-09 Anti-epcam immunoglobulins

Publications (2)

Publication Number Publication Date
CN1976951A CN1976951A (zh) 2007-06-06
CN1976951B true CN1976951B (zh) 2012-03-14

Family

ID=34838270

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800099764A Expired - Fee Related CN1976951B (zh) 2004-02-13 2005-02-09 抗EpCAM免疫球蛋白

Country Status (23)

Country Link
US (3) US20050180979A1 (cg-RX-API-DMAC7.html)
EP (2) EP1713830B1 (cg-RX-API-DMAC7.html)
JP (1) JP5220315B2 (cg-RX-API-DMAC7.html)
KR (1) KR101236224B1 (cg-RX-API-DMAC7.html)
CN (1) CN1976951B (cg-RX-API-DMAC7.html)
AT (1) ATE437186T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005215874B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0507660A (cg-RX-API-DMAC7.html)
CA (1) CA2555694C (cg-RX-API-DMAC7.html)
DE (1) DE602005015544D1 (cg-RX-API-DMAC7.html)
DK (1) DK1713830T3 (cg-RX-API-DMAC7.html)
EA (1) EA011951B1 (cg-RX-API-DMAC7.html)
ES (1) ES2328159T3 (cg-RX-API-DMAC7.html)
IL (1) IL177069A (cg-RX-API-DMAC7.html)
MX (1) MXPA06008942A (cg-RX-API-DMAC7.html)
NO (1) NO339364B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ549125A (cg-RX-API-DMAC7.html)
PL (1) PL1713830T3 (cg-RX-API-DMAC7.html)
PT (1) PT1713830E (cg-RX-API-DMAC7.html)
SI (1) SI1713830T1 (cg-RX-API-DMAC7.html)
UA (1) UA87128C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005080428A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200606083B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103275226A (zh) * 2013-06-09 2013-09-04 中国科学技术大学 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351919A1 (en) 2003-01-24 2018-07-25 University of Utah Methods of predicting mortality risk by determining telomere length
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
WO2007090670A1 (en) 2006-02-09 2007-08-16 Micromet Ag Treatment of metastatic breast cancer
US20100226922A1 (en) * 2006-06-08 2010-09-09 Dorothea Maetzel Specific protease inhibitors and their use in cancer therapy
EP1865001A1 (en) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Specific protease inhibitors and their use in cancer therapy
ATE512988T1 (de) 2007-04-04 2011-07-15 Sigma Tau Ind Farmaceuti Antikörper gegen epcam und anwendungen davon
EP2379747B1 (en) 2008-12-22 2013-07-03 University of Utah Research Foundation Monochrome multiplex quantitative pcr
CN102844443B (zh) * 2009-09-21 2014-08-06 保罗·沃尔菲什 用于甲状腺癌诊断和治疗的方法和组合物
JP6163502B2 (ja) * 2012-03-02 2017-07-12 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗上皮細胞接着分子（ＥｐＣＡＭ）抗体及びその使用方法
CN103409427B (zh) * 2012-09-24 2016-05-18 厦门大学 上皮细胞粘附分子的核酸适体EpCAM C及其制备方法
WO2014190138A2 (en) 2013-05-22 2014-11-27 Telomere Diagnostics, Inc. Measures of short telomere abundance
PL3553087T3 (pl) * 2014-01-08 2025-04-28 The Board Of Trustees Of The Leland Stanford Junior University Terapia celowana nowotworu złośliwego płuc
JP2018501799A (ja) 2014-12-30 2018-01-25 テロメア ダイアグノスティクス インコーポレイテッド マルチプレックス定量的ｐｃｒ
DK3377103T4 (en) * 2015-11-19 2025-05-19 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CN110035768A (zh) 2016-07-26 2019-07-19 泰莎治疗私人有限公司 嵌合抗原受体
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1252076A (zh) * 1997-04-14 2000-05-03 麦可麦脱生物药学研究有限公司 抗人抗原受体的新的生产方法及其用途
WO2002090566A2 (en) * 2001-05-03 2002-11-14 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20030175268A1 (en) * 2002-01-11 2003-09-18 Saint-Remy Jean-Marie R. Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
CA2485691A1 (en) * 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1252076A (zh) * 1997-04-14 2000-05-03 麦可麦脱生物药学研究有限公司 抗人抗原受体的新的生产方法及其用途
WO2002090566A2 (en) * 2001-05-03 2002-11-14 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEWIS L. D..Technology evaluation:ING-1, XOMA.CURRENT OPINION IN MOLECULAR THERAPEUTICS5 4.2003,5(4),433-436. *
LEWISL.D..Technologyevaluation:ING-1 XOMA.CURRENT OPINION IN MOLECULAR THERAPEUTICS5 4.2003

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103275226A (zh) * 2013-06-09 2013-09-04 中国科学技术大学 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用

Also Published As

Publication number Publication date
ATE437186T1 (de) 2009-08-15
WO2005080428A2 (en) 2005-09-01
EP2107071A3 (en) 2009-12-30
EA011951B1 (ru) 2009-06-30
BRPI0507660A (pt) 2007-07-17
SI1713830T1 (sl) 2009-10-31
US20120294873A1 (en) 2012-11-22
NO20064136L (no) 2006-11-07
US20070274982A1 (en) 2007-11-29
WO2005080428A3 (en) 2005-11-10
ZA200606083B (en) 2007-10-31
IL177069A0 (en) 2006-12-10
EP1713830B1 (en) 2009-07-22
EP2107071A2 (en) 2009-10-07
NO339364B1 (no) 2016-12-05
AU2005215874B2 (en) 2011-01-27
CA2555694A1 (en) 2005-09-01
KR101236224B1 (ko) 2013-02-22
AU2005215874A1 (en) 2005-09-01
EA200601386A1 (ru) 2007-06-29
UA87128C2 (ru) 2009-06-25
NZ549125A (en) 2008-09-26
JP2008500277A (ja) 2008-01-10
PL1713830T3 (pl) 2010-01-29
JP5220315B2 (ja) 2013-06-26
CA2555694C (en) 2013-04-16
ES2328159T3 (es) 2009-11-10
US20050180979A1 (en) 2005-08-18
IL177069A (en) 2010-11-30
KR20070009988A (ko) 2007-01-19
MXPA06008942A (es) 2007-01-26
CN1976951A (zh) 2007-06-06
PT1713830E (pt) 2009-10-19
HK1096103A1 (en) 2007-05-25
DE602005015544D1 (de) 2009-09-03
DK1713830T3 (da) 2009-10-12
EP1713830A2 (en) 2006-10-25

Similar Documents

Publication Publication Date Title
US20120294873A1 (en) ANTI-EpCAM IMMUNOGLOBULINS
AU2018241099B2 (en) Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
KR102349056B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
US20110274688A1 (en) Prevention of tumors with monoclonal antibodies against neu
WO1994022478A1 (en) PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
CN112203695B (zh) 用基于铂的试剂和抗组织因子抗体-药物偶联物的组合治疗癌症的方法
CN113260385B (zh) 抗vegf抗体和抗组织因子抗体-药物偶联物组合治疗癌症的方法
KR20140020922A (ko) 종양 개시 세포를 인지하는 항체와 항원 및 이의 용도
CN119868579A (zh) 抗组织因子抗体-药物偶联物及其在癌症治疗中的应用
CN112584872A (zh) 抗组织因子抗体-药物偶联物及其在癌症治疗中的用途
CN114650846A (zh) 用基于铂的试剂和抗组织因子抗体-药物偶联物的组合治疗癌症的方法
HK1096103B (en) Anti-epcam immunoglobulins
HK40005045B (zh) 用於治疗ror1癌症并抑制转移的抗体和疫苗
HK40051932A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
HK40045175A (en) Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120314

Termination date: 20190209